Competitive exclusion by autologous antibodies can prevent broad HIV-1 antibodies from arising

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 37, 2015, Pages 11654-11659

  Luo, Shishi ^a,b   Perelson, Alan S ^a  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Broadly neutralizing antibodies; Coevolutionary dynamics; Competitive exclusion; Human immunodeficiency virus; Mathematical modeling

Indexed keywords

AUTOANTIBODY; ENVELOPE PROTEIN; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; MONOCLONAL ANTIBODY; VIRUS ENVELOPE PROTEIN;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; MICROBIAL POPULATION DYNAMICS; NONHUMAN; PRIORITY JOURNAL; RECOGNITION; SIMULATION; SOMATIC MUTATION; STOCHASTIC MODEL; VACCINATION; VIRION; VIRUS ENTRY; VIRUS LOAD; VIRUS STRAIN; BINDING COMPETITION; CHEMISTRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MARKOV CHAIN; MUTATION; SERODIAGNOSIS; THEORETICAL MODEL;

AIDS VACCINES; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BINDING, COMPETITIVE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MODELS, THEORETICAL; MUTATION; NEUTRALIZATION TESTS; STOCHASTIC PROCESSES;

EID: 84941703210     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1505207112     Document Type: Article

References (41)

1. Kwong PD, Mascola JR, Nabel GJ (2011) Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb Perspect Med 1(1): A007278.
2. Kwong PD, Mascola JR (2012) Human antibodies that neutralize HIV-1: Identification, structures, and B cell ontogenies. Immunity 37(3): 412-425.
3. Haynes BF, Kelsoe G, Harrison SC, Kepler TB (2012) B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 30(5): 423-433.
4. Mascola JR, Haynes BF (2013) HIV-1 neutralizing antibodies: Understanding nature's pathways. Immunol Rev 254(1): 225-244.
5. Eroshkin AM, et al. (2014) bNAber: Database of broadly neutralizing HIV antibodies. Nucleic Acids Res 42(Database issue): D1133-D1139.
6. Wu X, et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329(5993): 856-861.
7. Wu X, et al. (2011) Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333(6049): 1593-1602.
8. Liao HX, et al. (2013) Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496(7446): 469-476.
9. Overbaugh J, Morris L (2012) The antibody response against HIV-1. Cold Spring Harb Perspect Med 2(1): A007039.
10. Shingai M, et al. (2014) Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med 211(10): 2061-2074.
11. Lifson JD, Haigwood NL (2012) Lessons in nonhuman primate models for AIDS vaccine research: From minefields to milestones. Cold Spring Harb Perspect Med 2(6): A007310.
12. Barouch DH, et al. (2013) Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503(7475): 224-228.
13. Shingai M, et al. (2013) Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503(7475): 277-280.
14. Haynes BF, Moody MA, Liao HX, Verkoczy L, Tomaras GD (2011) B cell responses to HIV-1 infection and vaccination: Pathways to preventing infection. Trends Mol Med 17(2): 108-116.
15. Kong L, Sattentau Q (2012) Antigenicity and immunogenicity in HIV-1 antibody-based vaccine design. J AIDS Clin Res S8: 3.
16. McCoy LE, Weiss RA (2013) Neutralizing antibodies to HIV-1 induced by immunization. J Exp Med 210(2): 209-223.
17. Breden F, et al. (2011) Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease. PLoS One 6(3): E16857.
18. Briney BS, Willis JR, Crowe JE, Jr (2012) Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS One 7(5): E36750.
19. Goo L, Chohan V, Nduati R, Overbaugh J (2014) Early development of broadly neutralizing antibodies in HIV-1-infected infants. Nat Med 20(6): 655-658.
20. Keele BF, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 105(21): 7552-7557.
21. Fischer W, et al. (2010) Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS One 5(8): E12303.
22. Smith DJ, Forrest S, Hightower RR, Perelson AS (1997) Deriving shape space parameters from immunological data. J Theor Biol 189(2): 141-150.
23. Smith DJ, Forrest S, Ackley DH, Perelson AS (1999) Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci USA 96(24): 14001-14006.
24. Chaudhury S, Reifman J, Wallqvist A (2014) Simulation of B cell affinity maturation explains enhanced antibody cross-reactivity induced by the polyvalent malaria vaccine AMA1. J Immunol 193(5): 2073-2086.
25. Percus JK, Percus OE, Perelson AS (1993) Predicting the size of the T-cell receptor and antibody combining region from consideration of efficient self-nonself discrimination. Proc Natl Acad Sci USA 90(5): 1691-1695.
26. Lee HY, Perelson AS (2007) In Silico Immunology, eds Flower DR, Timmis J (Springer, New York), pp 65-82.
27. Doria-Rose NA, et al. (2014) Developmental pathway for potent V1V2-directed HIVneutralizing antibodies. Nature 509(7498): 55-62.
28. Wang S, et al. (2015) Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies. Cell 160(4): 785-797.
29. Victora GD, Nussenzweig MC (2012) Germinal centers. Annu Rev Immunol 30: 429-457.
30. Murphy K (2011) Janeway's Immunobiology (Garland Science, New York), 8th Ed.
31. Wyatt R, Sodroski J (1998) The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 280(5371): 1884-1888.
32. Moore PL, et al. (2009) Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog 5(9): E1000598.
33. Chen L, et al. (2009) Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326(5956): 1123-1127.
34. Lynch RM, et al. (2015) HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. J Virol 89(8): 4201-4213.
35. Coffin J, Swanstrom R (2013) HIV pathogenesis: Dynamics and genetics of viral populations and infected cells. Cold Spring Harb Perspect Med 3(1): A012526.
36. Mascola JR, et al. (1996) Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 173(2): 340-348.
37. deCamp A, et al. (2014) Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 88(5): 2489-2507.
38. Malherbe DC, et al. (2011) Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J Virol 85(11): 5262-5274.
39. Forsell MN, et al. (2013) Independent expansion of epitope-specific plasma cell responses upon HIV-1 envelope glycoprotein immunization. J Immunol 191(1): 44-51.
40. Wrammert J, et al. (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208(1): 181-193.
41. Giudicelli V, Brochet X, Lefranc MP (2011) IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. Cold Spring Harb Protoc 2011(6): 695-715.